Risk Factors,PREvention and OutComes for CI-AKI in PatientS undErgoing PCI (PRECISE) (PRECISE)

June 5, 2025 updated by: Kaiyang Lin

Risk Factors,PREvention and outComes for Contrast-Induced Acute Kidney Injury in patientS undErgoing Percutaneous Coronary Intervention：a Single-center Cohort Study(PRECISE)

A prospective observational study included all patients undergoing percutaneous coronary intervention(PCI) in Fujian Provincial Hospital from January 1st 2012 to December 31st 2018. The aim was to determine the incidence,risk factors,prophylactic strategy and outcomes of CI-AKI in patients undergoing PCI.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

3030

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Fujian
      • Fuzhou,, Fujian, China, China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All Critically ill patients undergoing PCI at ICU were enrolled

Description

Inclusion Criteria:

  • Critically ill patients undergoing PCI at ICU

Exclusion Criteria:

  • pregnancy lactation end-stage renal disease (eGFR <15 mL/min/1.73 m2) long-term dialysis treatment intravascular administration of contrast medium within the last 7 or 3 days postoperatively

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CI-AKI
Time Frame: 5 year
This was due to acute kidney injury following the use of intravascular contrast media. Serum creatinine is the primary measuring modalities.
5 year
CKD
Time Frame: 5 year
Chronic renal structural and functional disorders that occurred during follow-up after administration of intravascular contrast agents, estimated glomerular filtration rate (eGFR) as the primary measuring modalities.
5 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
all-cause mortality
Time Frame: 5 year
Defined as deaths occurring during follow-up after discharge from EPCI, excluding force majeure factors such as natural disasters and car accidents,and the necessary information was gathered during follow-up.
5 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kaiyang Lin

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2012

Primary Completion (Actual)

January 1, 2018

Study Completion (Actual)

December 31, 2018

Study Registration Dates

First Submitted

May 26, 2025

First Submitted That Met QC Criteria

June 5, 2025

First Posted (Actual)

June 13, 2025

Study Record Updates

Last Update Posted (Actual)

June 13, 2025

Last Update Submitted That Met QC Criteria

June 5, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • K2019-07-011

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on CIN

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe